+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Systemic Scleroderma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Regions; Segment Forecast, 2021 - 2028

  • PDF Icon

    Report

  • 78 Pages
  • January 2021
  • Region: Global
  • Polaris Market Research
  • ID: 5261965
The global systemic scleroderma treatment market expected to reach USD 2.09 billion by 2028 according to this new study. The report “Systemic Scleroderma Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Immunosuppressors, Phosphodiesterase 5 inhibitors-PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Others); By Regions; Segment Forecast, 2021-2028”




The global market for systemic scleroderma treatment is anticipated to grow due to presence of innovative small molecule therapies, significant government backed funding, and increasing clinical trials for the concerned diseases. Moreover, the presence industry-academia collaborations in the developed countries are favoring the systemic scleroderma treatment industry growth.

The global market for systemic scleroderma treatment is fragmented based on drug class and region. The drug class market segment has been bifurcated into immuno-suppressors, phosphodiesterase 5 inhibitors-PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers, and others. The systemic scleroderma treatment industry region segment has been bifurcated into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Segment Highlights:


  • Immunosuppressors market segment accounted for over 60% of the overall market revenue share in 2020 and is expected to continue its dominance in systemic scleroderma treatment industry over the forecast period owing to higher efficiency and comparatively improved results
North America systemic scleroderma treatment industry is dominating the global market for systemic scleroderma treatment, holding over 40% of the market share throughout forecast period. Favorable reimbursement scenario and strong drug pipeline favoring the systemic scleroderma treatment industry growth
The market players including Roche Ltd.; United Therapeutics; Boehringer Ingelheim International GmbH together held a significant market share of global market for systemic scleroderma treatment in year 2020

List of Key Playersof Systemic Scleroderma Treatment Industry


Hoffmann La Roche Ltd.Johnson & Johnson Services, IncUnited Therapeutics
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Pfizer, IncEli Lilly and Company
  • Bayer AG
Mylan N.V.
Teva Pharmaceutical Industries Ltd.Others

The publisher has segmented systemic scleroderma treatment market report on the basis of drug class and region:


Systemic Scleroderma Treatment, Drug Class Outlook (Revenue-USD Million, 2016-2028)


  • Immunosuppressors
  • Phosphodiesterase 5 inhibitors-PHA
  • Endothelin Receptor Antagonists
  • Prostacyclin Analogues
  • Calcium Channel Blockers
  • Others

Systemic Scleroderma Treatment, Regional Outlook (Revenue-USD Million, 2016-2028)


  • North America
  • U.S
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Netherlands
  • Austria
  • Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
  • Central & South America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
Frequently Asked Questions about the Systemic Scleroderma Treatment Market

What is the estimated value of the Systemic Scleroderma Treatment Market?

The Systemic Scleroderma Treatment Market was estimated to be valued at $1.52 Billion in 2021.

What is the growth rate of the Systemic Scleroderma Treatment Market?

The growth rate of the Systemic Scleroderma Treatment Market is 4.1%, with an estimated value of $2.09 Billion by 2028.

What is the forecasted size of the Systemic Scleroderma Treatment Market?

The Systemic Scleroderma Treatment Market is estimated to be worth $2.09 Billion by 2028.

Who are the key companies in the Systemic Scleroderma Treatment Market?

Key companies in the Systemic Scleroderma Treatment Market include Roche Ltd., United Therapeutics, Boehringer Ingelheim International GmbH, Johnson & Johnson Services Inc., GlaxoSmithKline plc, Pfizer Inc., Eli Lilly, Company and Mylan N.V..

Table of Contents

1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Systemic Scleroderma Treatment Market Insights
4.1. Systemic Scleroderma Treatment - Industry snapshot
4.2. Systemic Scleroderma Treatment Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Emergence of innovative therapies
4.2.1.2. Rising prevalence of rare diseases
4.2.2. Restraints and Challenges
4.2.2.1. Lack of clinical evidence
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Systemic Scleroderma Treatment Market Industry trends
5. Global Systemic Scleroderma Treatment Market, by Drug Class
5.1. Key Findings
5.2. Introduction
5.2.1. Global Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
5.3. Immuno-suppressors
5.3.1. Global Systemic Scleroderma Treatment Market, by Immuno-suppressors, By Region, 2016 - 2028 (USD Million)
5.4. Phosphodiesterase 5 inhibitors-PHA
5.4.1. Global Systemic Scleroderma Treatment Market, by Phosphodiesterase 5 inhibitors-PHA, by Region, 2016 - 2028 (USD Million)
5.5. Endothelin Receptor Antagonists
5.5.1. Global Systemic Scleroderma Treatment Market, by Endothelin Receptor Antagonists, by Region, 2016 - 2028 (USD Million)
5.6. Prostacyclin Analogues
5.6.1. Global Systemic Scleroderma Treatment Market, by Prostacyclin Analogues, by Region, 2016 - 2028 (USD Million)
5.7. Calcium Channel Blockers
5.7.1. Global Systemic Scleroderma Treatment Market, by Calcium Channel Blockers, by Region, 2016 - 2028 (USD Million)
5.8. Others
5.8.1. Global Systemic Scleroderma Treatment Market, by Others, by Region, 2016 - 2028 (USD Million)
6. Systemic Scleroderma Treatment Market Assessment by Geography
6.1. Key findings
6.2. Introduction
6.2.1. Systemic Scleroderma Treatment Market Assessment, By Geography, 2016 - 2028 (USD Million)
6.3. Systemic Scleroderma Treatment Market - North America
6.3.1. North America: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.3.2. Systemic Scleroderma Treatment Market - U. S.
6.3.2.1. U. S.: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.3.3. Systemic Scleroderma Treatment Market - Canada
6.3.3.1. Canada.: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.4. Systemic Scleroderma Treatment Market - Europe
6.4.1. Europe: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.4.2. Systemic Scleroderma Treatment Market - UK
6.4.2.1. UK: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.4.3. Systemic Scleroderma Treatment Market - France
6.4.3.1. France: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.4.4. Systemic Scleroderma Treatment Market - Germany
6.4.4.1. Germany: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.4.5. Systemic Scleroderma Treatment Market - Italy
6.4.5.1. Italy: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.4.6. Systemic Scleroderma Treatment Market - Spain
6.4.6.1. Spain: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.4.7. Systemic Scleroderma Treatment Market - Netherlands
6.4.7.1. Netherlands: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.4.8. Systemic Scleroderma Treatment Market - Austria
6.4.8.1. Austria: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.5. Systemic Scleroderma Treatment Market - Asia-Pacific
6.5.1. Asia Pacific: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.5.2. Systemic Scleroderma Treatment Market - China
6.5.2.1. China: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.5.3. Systemic Scleroderma Treatment Market - India
6.5.3.1. India.: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.5.4. Systemic Scleroderma Treatment Market - Malaysia
6.5.4.1. Malaysia: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.5.5. Systemic Scleroderma Treatment Market - Japan
6.5.5.1. Japan: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.5.6. Systemic Scleroderma Treatment Market - Indonesia
6.5.6.1. Indonesia: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.5.7. Systemic Scleroderma Treatment Market - South Korea
6.5.7.1. South Korea.: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.6. Systemic Scleroderma Treatment Market - Middle East & Africa
6.6.1. Middle East & Africa.: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.6.2. Systemic Scleroderma Treatment Market - Saudi Arabia
6.6.2.1. Saudi Arabia.: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.6.3. Systemic Scleroderma Treatment Market - UAE
6.6.3.1. UAE: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.6.4. Systemic Scleroderma Treatment Market - Israel
6.6.4.1. Israel: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.6.5. Systemic Scleroderma Treatment Market - South Africa
6.6.5.1. South Africa: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.7. Systemic Scleroderma Treatment Market - Latin America
6.7.1. Latin America: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.7.2. Systemic Scleroderma Treatment Market - Mexico
6.7.2.1. Mexico.: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.7.3. Systemic Scleroderma Treatment Market - Brazil
6.7.3.1. Brazil.: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
6.7.4. Systemic Scleroderma Treatment Market - Argentina
6.7.4.1. Argentina.: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
7. Competitive Landscape
7.1. Expansion and Acquisition Analysis
7.1.1. Expansion
7.2. Partnerships/Collaborations/Agreements/Exhibitions
8. Company Profiles
8.1. F. Hoffman La Roche Ltd.
8.1.1. Company Overview
8.1.2. Financial Performance
8.1.3. Drug Class Benchmarking
8.1.4. Recent Development
8.2. Johnson & Johnson Services, Inc.
8.2.1. Company Overview
8.2.2. Financial Performance
8.2.3. Drug Class Benchmarking
8.2.4. Recent Development
8.3. United Therapeutics Corporation
8.3.1. Company Overview
8.3.2. Financial Performance
8.3.3. Drug Class Benchmarking
8.3.4. Recent Development
8.4. Boehringer Ingelheim International GmbH
8.4.1. Company Overview
8.4.2. Financial Performance
8.4.3. Drug Class Benchmarking
8.4.4. Recent Development
8.5. Novartis AG
8.5.1. Company Overview
8.5.2. Financial Performance
8.5.3. Drug Class Benchmarking
8.5.4. Recent Development
8.6. GlaxoSmithKline plc.
8.6.1. Company Overview
8.6.2. Financial Performance
8.6.3. Drug Class Benchmarking
8.6.4. Recent Development
8.7. Eli Lilly and Company
8.7.1. Company Overview
8.7.2. Financial Performance
8.7.3. Drug Class Benchmarking
8.7.4. Recent Development
8.8. Bayer AG
8.8.1. Company Overview
8.8.2. Financial Performance
8.8.3. Drug Class Benchmarking
8.8.4. Recent Development
8.9. Teva Pharmaceutical Industries Ltd.
8.9.1. Company Overview
8.9.2. Financial Performance
8.9.3. Drug Class Benchmarking
8.9.4. Recent Development
8.10. Gilead Sciences Inc.
8.10.1. Company Overview
8.10.2. Financial Performance
8.10.3. Drug Class Benchmarking
8.10.4. Recent Development
8.11. Pfizer Inc.
8.11.1. Company Overview
8.11.2. Financial Performance
8.11.3. Drug Class Benchmarking
8.11.4. Recent Development
8.12. Mylan N. V.
8.12.1. Company Overview
8.12.2. Financial Performance
8.12.3. Drug Class Benchmarking
8.12.4. Recent Development
List of Tables
Table 1. Global Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 2. Global Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 3. Systemic Scleroderma Treatment Market Assessment, By Geography, 2016 - 2028 (USD Million)
Table 4. North America: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 5. North America: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 6. U.S.: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 7. U.S.: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 8. Canada: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 9. Canada: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 10. Europe: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 11. Europe: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 12. UK: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 13. UK: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 14. France: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 15. France: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 16. Germany: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 17. Germany: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 18. Italy: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 19. Italy: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 20. Spain: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 21. Spain: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 22. Netherlands: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 23. Netherlands: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 24. Austria: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 25. Austria: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 26. Asia Pacific: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 27. Asia Pacific: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 28. China: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 29. China: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 30. India: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 31. India: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 32. Malaysia: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 33. Malaysia: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 34. Japan: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 35. Japan: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 36. Indonesia: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 37. Indonesia: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 38. South Korea: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 39. South Korea: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 40. Middle East & Africa: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 41. Middle East & Africa: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 42. Saudi Arabia: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 43. Saudi Arabia: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 44. UAE: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 45. UAE: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 46. Israel: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 47. Israel: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 48. South Africa: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 49. South Africa: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 50. Latin America: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 51. Latin America: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 52. Mexico: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 53. Mexico: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 54. Brazil: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 55. Brazil: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
Table 56. Argentina: Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Table 57. Argentina: Systemic Scleroderma Treatment Market, By Drug Class, 2016 - 2028 (USD Million)
List of Figures
Figure 1 Global Systemic Scleroderma Treatment Market, By Disease Type, 2016 - 2028 (USD Million)
Figure 2 Integrated Ecosystem
Figure 3 Research Methodology: Top Down & Bottom Up Approach
Figure 4 Market by Geography
Figure 5 Porter’s Five Forces
Figure 6 Market by Disease Type
Figure 7 Global Systemic Scleroderma Treatment Market, By Disease Type, 2020 & 2028 (USD Million)
Figure 8 Market by Drug Class
Figure 9 Global Systemic Scleroderma Treatment Market, By Drug Class, 2020 & 2028 (USD Million)
Figure 10 Systemic Scleroderma Treatment Market Assessment, By Geography, 2016 - 2028 (USD Million)
Figure 11 Strategic Analysis - Systemic Scleroderma Treatment Market

Companies Mentioned

  • Roche Ltd.
  • United Therapeutics
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services Inc.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Eli Lilly
  • Company
  • Bayer AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.